A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT ID: NCT02952534
Last Updated: 2023-06-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
277 participants
INTERVENTIONAL
2017-02-15
2021-07-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT02975934
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
NCT02987829
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
NCT03413995
TmPSMA-02 in mCRPC
NCT06046040
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
NCT04179396
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rucaparib
Oral rucaparib (monotherapy)
Rucaparib
Rucaparib will be administered daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rucaparib
Rucaparib will be administered daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
* Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL (1.73 nM)
* Experienced disease progression after having received at least 1 but no more than 2 prior next-generation androgen receptor-targeted therapies, and 1 prior taxane-based chemotherapy, for castration-resistant disease
* Have a deleterious mutation in BRCA1/2 or ATM, or molecular evidence of other homologous recombination deficiency
Exclusion Criteria
* Prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any platinum-based chemotherapy
* Symptomatic and/or untreated central nervous system metastases
* Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of rucaparib
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Foundation Medicine
INDUSTRY
pharmaand GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Mayo Clinc
Phoenix, Arizona, United States
Arizona Oncology Associates
Tucson, Arizona, United States
Alliance Research Centers
Laguna Hills, California, United States
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States
University of Southern California
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
Sharp Memorial Hospital
San Diego, California, United States
Pacific Hematology Oncology Associates
San Francisco, California, United States
San Francisco VA Health Care System
San Francisco, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Redwood Regional Medical Group
Santa Rosa, California, United States
Kaiser Permanente Medical Center (Vallejo)
Vallejo, California, United States
Rocky Mountain Cancer Centers
Aurora, Colorado, United States
Yale School of Medicine
New Haven, Connecticut, United States
4701 Ogletown Stanton Rd.
Newark, Delaware, United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Boca Raton Community Hospital, Inc.
Boca Raton, Florida, United States
Florida Cancer Specialists
Fort Myers, Florida, United States
University of Florida Health Cancer Center
Orlando, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Atlanta Urological Group
Atlanta, Georgia, United States
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Ochsner Medical Center
New Orleans, Louisiana, United States
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, United States
Walter Reed Hospital
Bethesda, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
VA Ann Arbor Healthcare System
Ann Arbor, Michigan, United States
Henry Ford Hospital
Detroit, Michigan, United States
Fairview Hospital
Edina, Minnesota, United States
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota, United States
Minnesota Veterans Research Institute
Minneapolis, Minnesota, United States
HCA Midwest Division - Kansas City
Kansas City, Missouri, United States
Alegent Health Bergan Mercy Hospital , GU Research Network
Omaha, Nebraska, United States
Nebraska Cancer Specialists
Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Premier Urology Associates dba/AdvanceMed Research
Lawrenceville, New Jersey, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Roswell Park
Buffalo, New York, United States
NYU Perlmutter Cancer Center
New York, New York, United States
Memorial Sloan Kettering CC
New York, New York, United States
Weill Cornell Medical College/NewYork-Presbyterian Hospital
New York, New York, United States
Premier Medical Group of the Hudson Valley PC
Poughkeepsie, New York, United States
University of Rochester
Rochester, New York, United States
SUNY Upstate Medical University
Syracuse, New York, United States
Carolina Urology Partners
Concord, North Carolina, United States
The Urology Group
Cincinnati, Ohio, United States
Kettering Cancer Center
Kettering, Ohio, United States
Clinical Research Solutions
Middleburg Heights, Ohio, United States
VA Portland Health Care System
Portland, Oregon, United States
Consultants in Medical Oncology Hematology
Horsham, Pennsylvania, United States
SCRI - Tennessee Oncology
Nashville, Tennessee, United States
Texas Oncology Medical City Dallas
Dallas, Texas, United States
UT Southwestern Medical Center
Dallas, Texas, United States
UT Health Science Center
Houston, Texas, United States
Texas Oncology - Tyler
Tyler, Texas, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
VA Puget Sound
Seattle, Washington, United States
Northern Cancer Insitute, St. Leonards
Saint Leonards, New South Wales, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Peninsula & Southeast Oncology
Frankston, Victoria, Australia
Barwon Health, University Hospital Geelong
Geelong, Victoria, Australia
Cabrini Hospital
Malvern, Victoria, Australia
Southside Cancer Care Centre
Miranda, , Australia
Orange Health Services
Orange, , Australia
St John of God Hospital, Subiaco
Subiaco, , Australia
Riverina Cancer Care Centre
Wagga Wagga, , Australia
ZNA Middelheim
Antwerp, , Belgium
Universitair Ziekenhuis Gent
Ghent, , Belgium
AZ Groeninge
Kortrijk, , Belgium
CHU Sart-Tilman
Liège, , Belgium
Equipe de Recherche Clinique, Département d'Oncologie/Hématologie
Liège, , Belgium
AZ DELTA
Roeselare, , Belgium
Juravinski Cancer Centre Hamilton Health Services
Hamilton, Ontario, Canada
London Health Science Center - Victoria Hospital
London, Ontario, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Princess Margaret Hospital
Toronto, , Canada
Copenhagen University Hospital
Copenhagen, , Denmark
Herlev Hospital
Herlev, , Denmark
Vejle Sygehus
Vejle, , Denmark
Centre François Baclesse
Caen, , France
Centre Georges François Leclerc
Dijon, , France
Clinique Victor Hugo Centre Jean Bernard
Le Mans, , France
Hôpital Privé La Louvière
Lille, , France
Polyclinique de Gentilly (Centre D'Oncologie De Gentilly)
Nancy, , France
Institut Curie
Paris, , France
Hôpital Privé des Côtes d'Armor
Plérin, , France
CRLCC Eugene Marquis
Rennes, , France
Gemeinschaftspraxis fur Hamatologie & Onkologie
Augsburg, , Germany
Charite Universitatsmedizin Berlin
Berlin, , Germany
Universitätsklinik Köln
Cologne, , Germany
Universitatsklinikum Carl Gustav Carus
Dresden, , Germany
Universitatsklinikum Dusseldorf
Düsseldorf, , Germany
Urologische Gemeinschaftspraxis
Emmendingen, , Germany
Universitaetsklinikum Hamburg-Eppendorf (UKE)
Hamburg, , Germany
Universitaetsklinikum Heidelberg
Heidelberg, , Germany
Universitatsklinikum Jena
Jena, , Germany
Universitätsklinikum Schleswig-Holstein
Lübeck, , Germany
Medizinischen Fakultät Mannheim der Universität Heidelberg
Mannheim, , Germany
Studienpraxis Urologie
Nürtingen, , Germany
University of Tuebingen
Tübingen, , Germany
Die Gesundhehitsunion DGU
Wuppertal, , Germany
Cork University Hospital
Cork, , Ireland
St. Vincent's University Hospital
Dublin, , Ireland
St James's Hospital
Dublin, , Ireland
Adelaide & Meath Hospital, Incorporating the National Children's Hospital
Dublin, , Ireland
Mater Misericordiae University Hospital
Dublin, , Ireland
Rambam Health Care Campus (RHCC), Rambam Medical Center
Haifa, , Israel
Hadassah University Hospital
Jerusalem, , Israel
Meir Medical Center
Kfar Saba, , Israel
Rabin Medical Center-Beilinson Campus
Petah Tikva, , Israel
Chaim Sheba Medical Center
Ramat Gan, , Israel
The Tel Aviv Sourasky Medical Center (Ichilov Hospital)
Tel Aviv, , Israel
Ospedale San Donato, Azienda USLSUDEST
Arezzo, , Italy
Ospedale Santa Maria delle Croci
Faenza, , Italy
IRCCS Istituto Nazionale dei Tumori (INT)
Milan, , Italy
IEO Instituto Europeo di Oncologia
Milan, , Italy
University of Modena and Reggio Emilia Medical Oncology
Modena, , Italy
Azienda Ospedaliera San Camillo-Forlanini
Rome, , Italy
Azienda Opsedaliera S. Maria di Terni
Terni, , Italy
Santa Chiara Hospital, Dept Medical Oncology
Trento, , Italy
Hospital Universitari Germans Trias i Pujol
Badalona, , Spain
Hospital del Mar, Servicio de Oncología
Barcelona, , Spain
Hospital Clínic i Provincial de Barcelona-Oncology
Barcelona, , Spain
Instituto Catalan de Oncologia
Barcelona, , Spain
Hospital Universitari Germans Trias i Pujol
Barcelona, , Spain
Hospital General Universitario de Guadalajara
Guadalajara, , Spain
Hospital Universitario Lucus Augusti.
Lugo, , Spain
MD Anderson Cancer Center - Madrid
Madrid, , Spain
Hospital Universitario Ramón y Cajal
Madrid, , Spain
Hospital 12 de Octubre
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital Puerta de Hierro-Majadahonda
Madrid, , Spain
Hospital Universitario Central de Asturias
Oviedo, , Spain
Corporacio Sanitaria Parc Tauli
Sabadell, , Spain
Marques de Valdecilla University Hospital (HUMV)
Santander, , Spain
Hospital Universitario Virgen del Rocío
Seville, , Spain
Instituto Valenciano de Oncologia IVO
Valencia, , Spain
Wexham Park Hospital
Slough, Berkshire, United Kingdom
Mount Vernon Cancer Centre
Northwood, England, United Kingdom
Royal Marsden Hospital
Sutton, Surrey, United Kingdom
Oxford University Hospitals
Headington, , United Kingdom
Royal Liverpool Hospital
Liverpool, , United Kingdom
London Health Science Center - Victoria Hospital
London, , United Kingdom
Guy's Hospital
London, , United Kingdom
Sarah Cannon Research Institutute - UK
London, , United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
Metropolitan Borough of Wirral, , United Kingdom
Southampton General Hospital
Southampton, , United Kingdom
Musgrove Park Hospital
Taunton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, Zhang J, Burke JM, Castellano D, Font A, Ganju V, Hardy-Bessard AC, McDermott R, Sautois B, Spaeth D, Voog E, Piulats JM, Pintus E, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Loehr A, Despain D, Simmons AD, Dowson M, Go J, Watkins SP, Chowdhury S. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023 Sep;84(3):321-330. doi: 10.1016/j.eururo.2023.05.021. Epub 2023 Jun 3.
Collins K, Cheng L. Reprint of: morphologic spectrum of treatment-related changes in prostate tissue and prostate cancer: an updated review. Hum Pathol. 2023 Mar;133:92-101. doi: 10.1016/j.humpath.2023.02.007. Epub 2023 Mar 8.
Green ML, Ma SC, Goble S, Giordano H, Maloney L, Simmons AD, Beltman J, Harding TC, Xiao JJ. Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors. Cancer Chemother Pharmacol. 2022 May;89(5):671-682. doi: 10.1007/s00280-022-04413-7. Epub 2022 Apr 10.
Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat Rev Urol. 2020 May;17(5):271-291. doi: 10.1038/s41585-020-0297-9. Epub 2020 Mar 17.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-003162-13
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CO-338-052
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.